Mapping the research addressing prescription drug monitoring programs: A scoping review

Abstract

Issues. Prescription drug monitoring programs are a harm minimisation intervention and clinical decision support tool that address the public health concern surrounding prescription drug misuse. Given the large number of studies published to date and the ongoing implementation of these programs, it is important to map the literature and identify areas for further research to improve practice. Approach. A scoping review was undertaken to identify the research on prescription drug monitoring programs published between January 2015 and April 2021. Key Findings. A total of 153 citations were included in this scoping review. The majority of the studies originated from the USA and were quantitative. Results on program effectiveness are mixed and mainly examine their association with opioid-related outcomes. Unintended consequences are revealed in the literature and this review also highlights barriers to program use. Implications. Overall, findings are mixed despite the large number of studies published to date. Mapping the literature identifies priority areas for further research that can advise policymakers and clinicians on practice improvement. Conclusion. Results on prescription drug monitoring program effectiveness are mixed and mainly examine their association with opioid-related outcomes. This review highlights barriers to prescription drug monitoring program effectiveness related to program use and system integration. Further research is needed in these areas to improve prescription drug monitoring program use and patient outcomes.

Health‐care practitioner use of prescription drug monitoring programs in clinical practice in Australia: A qualitative study

“…Therefore, PDMPs aim to support the mitigation of risk associated with opioid prescribing and dispensing [4,5]. Internationally, the research findings on opioid-related outcomes are mixed and the role of PDMPs in preventing opioid-related morbidity and mortality remains somewhat unclear [7,8].…”

“…It is commonly understood that practitioner PDMP uptake and use along with the identification of associated barriers plays an important role in whether these programs will achieve their objectives [8]. PDMPs may be underutilised due to a number of barriers [8,10,12,[16][17][18]. Barriers to use have been investigated in an attempt to address practitioner uptake and optimise PDMP use [19,20].…”

Barriers and facilitators related to healthcare practitioner use of real time prescription monitoring tools in Australia

“…It is widely accepted that practitioner RTPM tool utility and barriers to use play an important part in whether the tools will achieve their desired goals. Previous research has investigated barriers and facilitators to PDMP use by healthcare practitioners in the United States, however in Australia the literature is limited (9,(12)(13)(14)(15)(16)(17)(18)(19).…”

Eu3+-Doped Anionic Zinc-Based Organic Framework Ratio Fluorescence Sensing Platform: Supersensitive Visual Identification of Prescription Drugs

“…Environmental and biological monitoring of prescription drug concentrations is of ongoing interest. − Methods for prescription drug detection and quantification include high-performance liquid chromatography (HPLC), electrochemical analysis, and liquid chromatography–mass spectrometry (LC-MS). − In contrast to these quantification techniques, which are relatively time-consuming and expensive, , fluorescence-based platforms offer rapid response, high sensitivity, low cost, and ease of use . However, traditional single-signal fluorescence detection depends on the quantitative measurement of the output signal intensity, with instrumental errors and systematic background interferences leading to measurement error. , In contrast, dual-peak ratiometric fluorescence detection is inherently self-calibrating, significantly improving detection accuracy. − …”